"Dabigatran" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.
| Descriptor ID |
D000069604
|
| MeSH Number(s) |
D03.383.725.192 D03.633.100.103.280
|
| Concept/Terms |
Dabigatran- Dabigatran
- N-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-beta-alanine
|
Below are MeSH descriptors whose meaning is more general than "Dabigatran".
Below are MeSH descriptors whose meaning is more specific than "Dabigatran".
This graph shows the total number of publications written about "Dabigatran" by people in this website by year, and whether "Dabigatran" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 2 | 3 |
| 2017 | 32 | 23 | 55 |
| 2018 | 22 | 15 | 37 |
| 2019 | 11 | 2 | 13 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Dabigatran" by people in Profiles.
-
Potential Dexamethasone-Direct Oral Anticoagulant Drug Interaction: Is This a Concern in COVID? Ann Pharmacother. 2022 03; 56(3):319-329.
-
Prior use of anticoagulation is associated with a better survival in COVID-19. J Thromb Thrombolysis. 2021 Nov; 52(4):1207-1211.
-
Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination. Lancet. 2021 05 15; 397(10287):1842.
-
An unexpected case of recurrence of pulmonary embolism in a patient recovered from COVID19 in full regimen dose of direct oral anticoagulant drug. BMC Pulm Med. 2021 Mar 24; 21(1):102.
-
[Effect of anticoagulant therapy on the course of COVID-19 in comorbid patients]. Vopr Virusol. 2021 03 07; 66(1):40-46.
-
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. Eur Heart J. 2020 11 01; 41(41):4037-4046.
-
Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience. J Thromb Haemost. 2020 06; 18(6):1320-1323.
-
Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial. JAMA Neurol. 2019 12 01; 76(12):1457-1465.
-
Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI. JACC Cardiovasc Interv. 2019 08 26; 12(16):1553-1561.
-
Early-access programme in emergency care: idarucizumab use for rapid dabigatran reversal in critical care patients. Eur J Emerg Med. 2019 06; 26(3):230-231.